Efficacy and safety of recombinant human activated protein C for severe sepsis

New England Journal of Medicine

Volumn 344, Issue 10, 2001, Pages 699-709

  Bernard, Gordon R ^a   Vincent, Jean Louis ^b   Laterre, Pierre Francois ^c   LaRosa, Steven P ^d   Dhainaut, Jean Francois ^e   Lopez Rodriguez, Angel ^f   Steingrub, Jay S ^g   Garber, Gary E ^h,i   Helterbrand, Jeffrey D ^d   Ely, E Wesley ^a   Fisher, Charles J ^d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASME HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d ELI LILLY AND COMPANY   (United States)

^e Paris V University ^*  (France)

^f HOSPITAL INFANTA CRISTINA   (Spain)

^g BAYSTATE MEDICAL CENTER   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFECTION; INTERLEUKIN-6; PROSPECTIVE STUDIES; PROTEIN C; RECOMBINANT PROTEINS; RISK; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0035826096     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103083441001     Document Type: Article

References (34)

1. Sepsis: A new hypothesis for pathogenesis of the disease process
2. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial
3. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study
4. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
5. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987
6. Age-specific incidence and outcome of sepsis in the US
7. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C
8. Recombinant human protein C, protein S, and thrombomomodulin as antithrombotics
9. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans
10. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
11. Recombinant tumor necrosis induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1
12. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
13. Disseminated intravascular coagulation
14. The role of the endothelium in changes in procoagulant activity in sepsis
15. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
16. Inflammation and thrombosis: Mutual regulation by protein C
17. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
18. The protein C anticoagulant pathway
19. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies
20. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
21. Time course of hemostatic abnormalities in sepsis and its relation to outcome
22. Changes of the hemostatic network in critically ill patients - Is there a difference between sepsis, trauma, and neurosurgery patients?
23. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
24. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
25. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis
26. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
27. Characterization and novel purification of recombinant human protein C from three mammalian cell lines
28. Discrete sequential boundaries for clinical trials
29. APACHE II: A severity of disease classification system
30. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V
31. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V
32. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
33. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation
34. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide